文献速递骨肿瘤

术中体外照射与冷冻处理对带瘤自体骨移植物在生物学重建中显示等效结果

Intraoperative Extracorporeal Irradiation and Frozen Treatment on Tumor-bearing Autografts Show Equivalent Outcomes for Biologic Reconstruction.
PubMed 文献 · Clin Orthop Relat Res · 2018-01-01

研究比较体外照射与冷冻处理带瘤自体骨移植物在生物学肢体 salvage 重建中的效果。164例高级别骨肉瘤患者中,79例接受体外照射自体骨移植,85例接受冷冻处理自体骨移植。两组在18个月内达到骨愈合的比例、移植物相关并发症及移植物来源复发方面无显著差异;5年总生存率分别为83%和84%(p=0.69)。

要点

  • 体外照射与冷冻处理自体骨移植在6、9、12、18个月累积愈合比例上无差异。
  • 冷冻处理组在软骨下骨亚标准评分上更高(p=0.03)。
  • 两组移植物失败、肢体截肢累积发生率及5年总生存率无差异。

核心结论

  • 在本研究可用数据中,体外照射与冷冻处理带瘤自体骨移植物在肿瘤复发发生率上无差异。
  • 作者将ISOLS标准中移植物介导的肿瘤进展分为宿主或移植物来源并发症(5B和5C型)。
  • 作者认为继续评估两组10年生存率有助于阐明100个月后可能出现的差异。

研究设计与样本

  • 研究纳入研究期间治疗的333例高级别骨肉瘤患者,排除169例,最终入组164例。
  • 79例接受体外照射处理的自体骨移植物,85例接受冷冻处理的自体骨移植物。
  • 体外照射组平均随访82±54个月,冷冻自体骨移植组平均随访70±25个月,1例失访。
  • 并发症和移植物失败采用适配生物学和可延长重建的ISOLS系统进行表征。
  • 主要研究终点为术后6、9、12和18个月达到影像学愈合且宿主-移植物融合ISOLS分级为fair或good的患者比例。

主要发现

  • 在6、9、12和18个月,两组累积达到愈合的患者比例无差异。
  • 影像学评估显示比较标准的平均评分无差异,但在软骨下骨亚标准中,冷冻处理自体骨移植组有更多患者评分更高(p=0.03)。
  • 导致二次手术的并发症在软组织失败(1B型)、骨不连(2B型)、结构失败(3A和3B型)或感染(4A和4B型)方面,体外照射与冷冻自体骨移植之间无差异。
  • 未发现移植物来源肿瘤复发,两组间起源于软组织的5A型肿瘤进展无差异(比值比0.8;95% CI,0.3-2.1;p=0.7)。
  • 两组移植物失败和肢体截肢的累积发生率无差异;体外照射组和冷冻自体骨移植组的5年总生存率分别为83%和84%(p=0.69)。

关键数值与推荐

  • 体外照射组5年总生存率83%,冷冻自体骨移植组84%(p=0.69)。
  • 5A型肿瘤进展比值比0.8(95% CI,0.3-2.1;p=0.7)。
  • 软骨下骨亚标准评分冷冻处理组更高(p=0.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immediately recycling the resected bone segment in a biologic limb salvage reconstruction is an option after wide resection of bone. Intraoperative extracorporeal irradiation and freezing are the two major tumor-killing techniques applied on the fresh tumor-bearing autografts. However, graft-derived tumor recurrence and complications are concerns affecting graft survival. QUESTIONS/PURPOSES: We therefore asked: (1) Is there a difference in the proportion of patients achieving union by 18 months after surgery between the groups with extracorporeal-irradiated autografts and frozen-treated autografts? (2) Is there any difference in the frequency of graft-related complications for patients receiving either an extracorporeal-irradiated or a frozen-treated autograft? (3) Is there a difference between the techniques in terms of graft-derived recurrence? (4) Are there differences in failure-free grafts, and limb and overall survivorship between autografts treated by extracorporeal irradiation or by freezing? METHODS: During the study period we treated a total of 333 patients with high-grade osteosarcoma. One hundred sixty-nine patients were excluded. Overall, 79 of the enrolled 164 patients received recycled autografts treated with extracorporeal irradiation whereas the other 85 received frozen-treated autografts. The mean followup was 82 ± 54 months for the extracorporeal irradiation group and 70 ± 25 months for the frozen autograft group, and one patient was lost to followup. Complications and graft failure (revision required for primary graft removal) were characterized by adapting the International Society of Limb Society (ISOLS) system modified for inclusion of biologic and expandable reconstruction. The primary study endpoints were the proportion of patients in each group who achieved radiographic union, and had an ISOLS grade of fair or good host graft fusion at 6, 9, 12, and 18 months after surgery. Five-year survival data for graft failure and limb amputation were analyzed by a cumulative incidence function regression model whereas the Kaplan-Meier function was used to test the 5-year overall survival rate between the two techniques. RESULTS: With the numbers available, no differences were found in the accumulated proportion of patients achieving union between the groups at 6, 9, 12, and 18 months. Radiographic evaluation did not show differences in the average scores of compared criteria. However in the subchondral bone subcriterion, more patients receiving frozen-treated autografts had higher scores (p = 0.03). Complications leading to a second surgery were not different between extracorporeal irradiation and frozen autografts in aspects of soft tissue failure (Type 1B), nonunion (Type 2B), structural failure (Type 3A and Type 3B), or infection (Type 4A and Type 4B). No graft-originating tumor recurrence was found and there was no difference in Type 5A tumor progression originating from soft tissue in the groups (odds ratio, 0.8; 95% CI, 0.3-2.1; p = 0.7). Neither group showed a difference in the cumulative incidence for graft failure and limb amputation. Five-year overall survival rates were 83% and 84% (p = 0.69) for extracorporeal-irradiated and frozen autografts respectively. A decrease in survivorship was seen at 50 to 100 months after surgery for the extracorporeal irradiation group. CONCLUSION: We segregated the ISOLS criteria evaluating the graft-mediated tumor progression into host- or graft-derived complications (Types 5B and 5C) in this study. With the available data, there was no difference in the incidence of tumor recurrence derived from irradiation- or frozen-treated autografts. Ongoing evaluations comparing 10-year survivorship for both groups will be helpful to elucidate the possible difference found after 100 months. LEVEL OF EVIDENCE LEVEL: III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Wu PK, Chen CF, Chen CM, et al. Intraoperative Extracorporeal Irradiation and Frozen Treatment on Tumor-bearing Autografts Show Equivalent Outcomes for Biologic Reconstruction. Clin Orthop Relat Res. 2018. PMID: 29470232. doi:10.1007/s11999.0000000000000022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。